In conclusion, the sVNT can be used as an additional assay to estimate the neutralising antibody status of COVID-19 infected of vaccinated individuals, and in cohort studies to confirm results of more routine immuno-assays like IgG, IgM and/or IgA ELISAs and CLIAs. This evidence concerns the gene CD40LG and COVID-19.